extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
e0efaf0f49
commit
999be4e309
7 changed files with 78 additions and 1 deletions
|
|
@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
|
|||
|
||||
MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's 192K patient study shows medical costs rise 23% in year 1 but only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests GLP-1s are cost-saving for long-term risk-bearers, not inflationary—the 'inflationary through 2035' claim may only apply to short-term payers like employers with high turnover.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
- Nature Medicine: additive benefits with SGLT2 inhibitors
|
||||
- First GLP-1 to receive FDA indication for CKD in T2D patients
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon study adds cancer risk reduction to the multi-organ protection profile: 50% lower ovarian cancer and 14% lower breast cancer in female users, plus lower rates of osteoporosis, rheumatoid arthritis, and alcohol/drug abuse hospitalizations. The sex-differential in MACE (47% female vs 26% male) suggests organ-specific protection may be stronger in women.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon data shows benefits scale dramatically with adherence: 80%+ adherent users show 9 percentage point lower cost growth (vs 6 points for all users) in diabetes and 7 points lower (vs 3 points) in weight loss. This confirms that the adherence crisis undermines the economic case, but also shows the potential value if adherence can be improved.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's real-world data confirms downstream cost savings materialize after 12-18 months, with diabetes patients showing 6-9 percentage point lower medical cost growth at 30 months. This validates the kidney protection economic model—savings are real but require long-term risk-bearing to capture.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -297,6 +297,12 @@ The Commonwealth Fund's 2024 international comparison provides evidence that the
|
|||
|
||||
C-SNP growth of 71% in one year shows MA plans are rapidly building chronic disease management infrastructure. With 21% of MA enrollment now in SNPs (up from 14% in 2020), the market is structurally shifting toward continuous care management models that align with prevention-first economics.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
GLP-1 economics demonstrate the payment alignment requirement: identical drug, identical clinical outcomes, but opposite financial incentives for short-term (employer) vs long-term (MA) risk-bearers. The 12-18 month lag between costs and savings means only aligned payment structures can profit from prevention.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
|
||||
"glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs 6% for non-users
|
||||
- Diabetes indication: 6 percentage points lower cost growth at 30 months; 9 points with 80%+ adherence
|
||||
- Weight loss indication: 3 points lower cost growth at 18 months; 7 points with consistent use
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- MACE reduction: 47% for women, 26% for men among adherent users
|
||||
- Also associated with lower osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations
|
||||
|
|
|
|||
Loading…
Reference in a new issue